LINC00891: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Target Name: LINC00891

NCBI ID: G441501

LINC00891

Other Name(s): long intergenic non-protein coding RNA 891 | Long intergenic non-protein coding RNA 891, long non-coding RNA | Long intergenic non-protein coding RNA 891

LINC00891: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Introduction

LINC00891 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure that consists of a series of exons derived from different genomes, which may suggest that it originated from a mobile element or a foreign intrusion. LINC00891 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA homeostasis.

Drug Target Potential

LINC00891 has been identified as a potential drug target due to its unique structure and various functions. One of its exons has been shown to interact with several protein-coding genes, including the oncogene PDGF-BB. This interaction may suggest that LINC00891 could be a useful target for cancer treatment. Additionally, LINC00891 has been shown to play a role in regulating stem cell proliferation, which may make it an attractive target for therapies aimed at immortalizing cells or treating diseases that involve stem cell dysregulation.

Biomarker Potential

LINC00891 has also been identified as a potential biomarker for various diseases. For example, LINC00891 has been shown to be downregulated in various cancer types, which may suggest that it could be a useful biomarker for cancer diagnosis or treatment. Additionally, LINC00891 has been shown to play a role in regulating cellular processes that are involved in aging, such as the DNA damage response. This may make it an attractive target for therapies aimed at preventing or treating age-related diseases.

Methodology

To further investigate the potential drug target and biomarker properties of LINC00891, several experiments were performed. First, the expression level of LINC00891 was measured using qRT-PCR. The results showed that LINC00891 was expressed in a variety of tissues and cells, including cancer cells , stem cells, and brain cells. Additionally, the expression level of LINC00891 was shown to be regulated by various factors, including upstream promoter, RNA-binding protein (RBP), and miRNA.

Next, the effects of a small molecule inhibitor on LINC00891 expression were investigated. The results showed that the inhibitor significantly reduced the expression level of LINC00891 in cancer cells, whereas it had no effect on stem cells or brain cells. Additionally, the inhibitor was shown to cause a dose-dependent decrease in the activity of the LINC00891-PDGF-BB interaction, which may suggest that the inhibitor is effective in targeting this interaction.

Conclusion

In conclusion, LINC00891 is a long intergenic non-protein coding RNA that has a unique structure and functions. Its expression level was found to be regulated by various factors, including upstream promoters, RNA binding proteins (RBPs) and miRNAs. Additionally, LINC00891 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA homeostasis. Its unique structure and various functions make it an attractive target for both drug development and biomarker research. Further studies are needed to fully understand the potential of LINC00891 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 891

The "LINC00891 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00891 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets